

Claims

1. In situ produced macroporous biomedical polyurethane-amide material based on chain extended isocyanate terminated polyester prepolymer units, wherein the said chain extension has been done with at least one dicarboxylic acid or a hydroxy-carboxylic acid.
- 5 2. Polyurethane-amide according to claim 1, wherein the material has a pore structure, wherein the amount of pores having a pore size of $>450\text{ }\mu\text{m}$ is less than 10% by volume.
3. Polyurethane-amide according to claim 1 or 2, wherein the material has an open cell structure.
- 10 4. Polyurethane-amide according to claim 1-3, wherein the said prepolymer is a prepolymer of soft polyester segments, having a glass transition temperature below 40°C , said prepolymer further optionally containing polyether-polyol segments.
5. Polyurethane-amide according to claim 1-4, wherein the material shows
15 phase separation into hard and soft phases.
6. Polyurethane-amide according to claim 1-5, wherein the polyester is based on a polyester prepared by ringopening polymerisation, preferably a random copolyester.
7. Polyurethane-amide according to claim 6, wherein the random
20 copolyester is a copolyester of lactide, glycolide, trimethylene carbonate and/or ϵ -caprolacton.
8. Polyurethane-amide according to claim 1-7, further comprising an additional diol segment.
9. Polyurethane-amide according to claim 8, wherein the said additional
25 diol segment is a polyether or a polyester segment.

10. Polyurethane-amide according to claim 8 or 9, wherein the said diol segment is incorporated in the material during the reaction of the prepolymer with the chain extender.
11. Polyurethane-amide according to claim 1-10, based on a copolyester of
5 lactide and ϵ -caprolacton containing 5 to 95, preferably 40-60 % of units of lactide and 5 to 95, preferably 40-60 % of units of ϵ -caprolacton, based on number.
12. In situ produced macroporous biomedical polyurethane-amide material based on chain extended prepolymer units of biocompatible soft polyester
10 segments and on hard urethane-amide segments, said material having a compression modulus of at least 100 kPa and a pore size distribution less than 10 vol.% of pores having a pore size $> 450 \mu\text{m}$.
13. Macroporous biomedical polyurethane-amide according to claim 12, showing phase separation between soft and hard segments.
14. Macroporous biomedical polyurethane-amide according to claim 12 or
15 13, having an open cell structure.
15. Macroporous biomedical polyurethane-amide according to claim 12-14, said material being biodegradable.
16. Process for the preparation of a macroporous biomedical polyurethane-
20 amide according to claim 1-15, said process being solvent free and comprising preparing an isocyanate terminated polyester prepolymer, mixing the prepolymer with at least one chain extender selected from the group of dicarboxylic acids and hydroxycarboxylic acids, reacting the mixture to produce the macroporous biomedical polyurethane.
17. Process according to claim 16, wherein the said chain extender is adipic
25 acid.
18. Process according to claim 16 or 17, wherein the prepolymer is mixed with salt crystals of a required particle size to assist in the generation of suitable pores, and leaching out the salt crystals after the chain extension has
30 been completed.

